Clinical and community pharmacist's role in the COVID-19 pandemic
DOI:
https://doi.org/10.33448/rsd-v9i7.4856Keywords:
Clinical pharmacist; Community pharmacist; Pharmaceutical care; Pandemic; COVID-19.Abstract
This research aims to present the importance of the pharmaceutical professional's performance in face of the COVID-19 pandemic. It is a bibliographic review that was conducted based on data collected from the Science Direct, Pubmed, Medline and official Brazilian government websites. As inclusion criteria, articles from 2019 and 2020 were selected from September 15, 2019 to May 13, 2020, in English and complete dealing with the theme in question. The results found indicate that the performance of the pharmacist in the health teams that are facing this pandemic is fundamental since this professional has the knowledge of the drugs, their interactions and adverse reactions to drugs. The management of the hospital pharmacy at this time is essential so that there is no shortage of medication or waste, and within community pharmacies the pharmacist's performance is through information on prevention and control of COVID-19, as well as guidance for those patients who already have other comorbidities and make continuous use of medication. Thus, the community and clinical pharmacist who is acting in the face of this pandemic has become an indispensable professional since he has full support to integrate the health teams to contribute with his knowledge and skill about the drugs.
References
Brasil. (2020). Organização Pan-Americana da Saúde. Organização Mundial da Saúde. From: https://www.paho.org/bra/.
Cadogan CA & Hughes CM (2020). On the frontline against COVID-19: Community pharmacistis contribution during a public health crisis. Research in Social and Administrative Pharmacy. 2020 Mar 31.
Conselho Federal de Farmácia. (2020). Guia para estratificação de risco de suspeitos de Covid-19 e delineamento de cuidado farmacêutico para farmácias comunitárias. From: http://covid19.cff.org.br/wp-content/uploads/2020/05/delineamento_versao4.pdf
Conselho Federal de Farmácia. (2020). Plano de resposta para as farmácias privadas e públicas da atenção primária. From: http://covid19.cff.org.br/wp-content/uploads/2020 /05/Coronav%C3%ADrus-orienta%C3%A7%C3%B5es-a-Farm%C3%A1cias-da-APS-no-SUS-1.pdf.
Hua X, Gu M, Zeng F, Hu H, Zhou T, Zhang & Y, Shi C (2020). Pharmacy administration and pharmaceutical care practice in a module hospital during the COVID-19 epidemic. Journal of The Pharmacists Association. 2020 Apr 10.
Jaber D, Aburuz S, Hammad EA, El-Refae H & Basheti I. (2019). Patients attitude and willingness to pay for pharmaceutical care: an internacional message from a developing country. Research in Social and Administrative Pharmacy. 2019 Sep 15.
Khodadadi E, Maroufi P, Khodadadi E, Esposito I, Ganbarov K, Espsoito S, Yousefi M, Zeinalzadeh E & Kafil HS (2020). Study of combining virtual screening and antiviral treatments of the Sars-Cov-2 (Covid- 19). Microbial Pathogenesis. 104241. 2020 May 5.
Kretchy IA, Asiedu-Danso M & Kretchy J (2020). Medication management and adherence during the COVID-19 pandemic: perspectives and experiences from low-and middle- income coutries. Research in Social and Administrative Pharmacy. 2020 Apr 15.
Liu S, Luo P, Tang M, Hu Q, Polidoro JP, Sun S & Gong Z (2020). Providing pharmacy during the coronavirus pandemic. Intern. Journal of Clinical Pharmacy. 1-6. 2020 Mar 28.
Lythgoe M, Middleton P (2020). Ongoing clinical trials for the management of the COVID-19 pandemic. Trends in Pharmacological Sciences, 41, 363-82. 2020 Apr 9.
Park ES (2020). Epidemiology, virology, and clinical features of severe acute respiratory syndrome- coronavirus- 2 (SARS CoV-2; Coronavirus disease-19). Clinical and Experimental Pediatrics, 63(4), 119-24. 2020 Apr 2.
Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, Perricone R, Gerli, R (2020). The anti-viral facet f anti-rheumatic drugs: lessons form COVID:19. Journal of Autoimmunity. 102468. 2020 Apr 17.
Singh AK, Singh A, Singh R & Misra A. (2020). Remdesivir in COVID-19: a critical review of pharmacology pre-clinical and clinical studies. Diabetes & Metabolic Syndrome. 13 May 2020.
Song, Z., Hu, Y., Zheng, S., Yang, L., Zhao, R. (2020). Hospital pharmacists care for hospitalized patients with COVID-19: recommendations and guidance from clinical experience. Research in Social and Administrative Pharmacy. 2020 Apr 3.
Tay, M.Z., Poh, C.M., Rénia, L., MacAry, P.A., Ng, L.F.P. (2020). The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews. Immunology. 1-12. 2020 Apr 28.
Tobaigy, M., Qashqary, M., Al-Dahery, S., Mujallad, A., Hershan, A., Kamal, M.A, Helmi, N. (2020). Therapeutic Management of COVID-19 patients: a systematic review. Infection Revention in Practice. 100061. 2020 Apr 17.
Xie, X., Muruato, A., Lokugamage, K.G., Narayanan, K., Zhang, X., Zou, J., Liu, J., Schindewolf, C., Bopp, N.E., Aguilar, P.V., Plante, K. S., Weaver, S.C, Makino, S., LeDuc, J.W., Menachery, V.D., Shi, P. (2020). An infectious cDNA clone of SARS-CoV-2. Cell Host & Microbe. 2020 Apr 13.
Ying, W., Qian, Y., & Kun, Z. (2020). Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic. Research in Social and Administrative Pharmacy. 2020 Apr 6.
Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y., Li, Y. (2020). The epidemiology, diagnosis and treatment of COVID-19. International Journal of Antimicrobial Agents. 105955. 2020 Mar 28.
Zhang, J., Xie, B., Hashimoto, K. (2020). Current status of potential therapeutic candidates for the COVID-19 crisis. Brain, Behavior, and Immunity. 2020 Apr 22.
Zheng, S., Yang, L., Zhou, P., Li, H., Liu, F., Zhao, R. (2020). Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: a China perspective. Research in Social and Administrative Pharmacy. 2020 Mar 26.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.